Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of agomelatine oral administration (25 mg/day) in elderly patients suffering from major depressive disorder: an 6-week, randomised, double-blind, fixed-dose, parallel groups, placebo-controlled, international, multicentre study followed by an extension double-blind treatment period of 18 weeks.

Next Previous
X
Search
Trial Profile

Efficacy and safety of agomelatine oral administration (25 mg/day) in elderly patients suffering from major depressive disorder: an 6-week, randomised, double-blind, fixed-dose, parallel groups, placebo-controlled, international, multicentre study followed by an extension double-blind treatment period of 18 weeks.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Agomelatine (Primary)
  • Indications Major depressive disorder
  • Focus Therapeutic Use

    • Most Recent Events

    • 12 Apr 2017 Primary endpoint (The MADRS total score over 6 weeks) has been met.
    • 12 Apr 2017 New trial record
    • 05 Apr 2017 Results assessing safety and efficacy of Agomelatine using patient data from two phase III trials (ISRCTN57507360 and see CTP 283683), published in the International Clinical Psychopharmacology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top